Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| POINT Biopharma Global Inc.TXAC · Entity 95793 | Director · Chief Financial Officer | July 07, 2020 | July 08, 2020 |
| Research Alliance Corp IIIRACC · Entity 6369 | Director · Chief Executive Officer · 10% owner | May 21, 2026 | May 21, 2026 |
| Research Alliance Corp IVRACD · Entity 6687 | Director · Chief Executive Officer · 10% owner | July 14, 2026 | July 16, 2026 |
| Research Alliance Corp. IIRACB · Entity 122733 | Director · Chief Investment Officer | March 17, 2021 | March 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
POINT Biopharma Global Inc.
Report date July 07, 2020 · Filed July 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2020-07-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F3: The shares of Class B common stock owned by the Reporting Person includes up to 375,000 shares that are subject to forfeiture in the event the underwriters of the initial public offering of the issuer's securities do not exercise in full their over-allotment option as described in the issuer's registration statement. F2: Consists of shares held by Therapeutics Acquisition Holdings, LLC ("Holdings") of which the Reporting Person is the manager. As such, the Reporting Person has voting and investment discretion and may be deemed to have beneficial ownership with respect to the shares of Class B Common Stock held by Holdings. of the common stock held directly by our sponsor. The Reporting Person disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
F2: Consists of shares held by Therapeutics Acquisition Holdings, LLC ("Holdings") of which the Reporting Person is the manager. As such, the Reporting Person has voting and investment discretion and may be deemed to have beneficial ownership with respect to the shares of Class B Common Stock held by Holdings. of the common stock held directly by our sponsor. The Reporting Person disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
F3: The shares of Class B common stock owned by the Reporting Person includes up to 375,000 shares that are subject to forfeiture in the event the underwriters of the initial public offering of the issuer's securities do not exercise in full their over-allotment option as described in the issuer's registration statement.
Research Alliance Corp III
Report date May 21, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Research Alliance Holdings III LLC | 275,000 |
Reported balance
After 2026-05-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 275,000 · Balance 275,000 F1: Mr. Hammond is the sole director of Research Alliance Holdings III LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Hammond is the sole director of Research Alliance Holdings III LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any.
Research Alliance Corp IV
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Research Alliance Holdings IV LLC | 275,000 |
Reported balance
After 2026-07-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-14 · Grant · Acquired 275,000 · Balance 275,000 F1: Mr. Hammond is the sole director of Research Alliance Holdings IV LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Hammond is the sole director of Research Alliance Holdings IV LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any.
Research Alliance Corp. II
Report date March 17, 2021 · Filed March 18, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 20:28 UTC | Research Alliance Corp IV RACD · Entity 6687 | GrantClass A Ordinary Shares | 275,000 | $10.00 | $2,750,000.00 |
DisclosureSEC source: 0001817056-26-000008 · form4-07162026_080706.xml · nonDerivative · entry 1 Hammond Matthew · CIK 0001817056 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Research Alliance Holdings IV LLC Disclosed balance after: 275,000 F1 · ownership.nature: Mr. Hammond is the sole director of Research Alliance Holdings IV LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 21, 2026 Filed May 21, 2026 20:14 UTC | Research Alliance Corp III RACC · Entity 6369 | GrantClass A Ordinary Shares | 275,000 | $10.00 | $2,750,000.00 |
DisclosureSEC source: 0001817056-26-000003 · form4-05212026_080516.xml · nonDerivative · entry 1 Hammond Matthew · CIK 0001817056 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Research Alliance Holdings III LLC Disclosed balance after: 275,000 F1 · ownership.nature: Mr. Hammond is the sole director of Research Alliance Holdings III LLC (the "Sponsor"). As such, he has voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. Mr. Hammond disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.